Compugen (CGEN) Cash & Current Investments (2009 - 2026)
Compugen (CGEN) posted quarterly Cash & Current Investments of $91.8 million for Q1 2026, up 29.13% year-over-year from $71.1 million in Q1 2025, and down 32.71% on a QoQ basis from $136.4 million in Q4 2025.
Analysis
Compugen (CGEN) Cash & Current Investments (2009 - 2026) Analysis & Trends
Compugen has reported Cash & Current Investments for 18 years, with the latest figure at $91.8 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $91.8 million, up 29.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.8 million (up 29.13% YoY), and the FY2025 annual result was $136.4 million, up 71.25% from the prior year.
- Cash & Current Investments fell to $91.8 million in Q1 2026, from $136.4 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $136.4 million in Q4 2025 and troughed at $38.9 million in Q4 2023.
- A 5-year average of $77.0 million and a median of $74.3 million in 2023 frame the typical range for Cash & Current Investments.
- The widest annual swing landed in 2023, when Cash & Current Investments plunged 53.28%; it then surged 104.47% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $83.3 million in 2022, then plunged by 53.28% to $38.9 million in 2023, then surged by 104.47% to $79.6 million in 2024, then soared by 71.25% to $136.4 million in 2025, then sank by 32.71% to $91.8 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $91.8 million in Q1 2026, $136.4 million in Q4 2025, and $59.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 | 85.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.62 Mn |
| Mar 31, 2026 | 91.75 Mn |
| Dec 31, 2025 | 136.36 Mn |
| Sep 30, 2025 | 59.36 Mn |
| Jun 30, 2025 | 65.00 Mn |
| Mar 31, 2025 | 71.06 Mn |
| Dec 31, 2024 | 79.63 Mn |
| Sep 30, 2024 | 79.57 Mn |
| Jun 30, 2024 | 59.32 Mn |
| Mar 31, 2024 | 69.05 Mn |
| Dec 31, 2023 | 38.94 Mn |
| Sep 30, 2023 | 47.78 Mn |
| Jun 30, 2023 | 61.98 Mn |
| Mar 31, 2023 | 74.32 Mn |
| Dec 31, 2022 | 83.35 Mn |
| Sep 30, 2022 | 88.21 Mn |
| Jun 30, 2022 | 97.29 Mn |
| Mar 31, 2022 | 106.82 Mn |
| Dec 31, 2021 | 117.05 Mn |
| Sep 30, 2021 | 102.25 Mn |